Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 136

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 136
---
 |   |     | $ | (1.11 | ) |

<div align='center'>72</div>

The
number of shares of Common Stock that will be outstanding after this offering is based on
1,475,426 shares of Common Stock outstanding as of September 30, 2024 (giving retroactive
effect to the Reverse Stock Split), and excludes:

| ● | 26,575                                                 
 shares of Common Stock underlying outstanding options; |

| ● | 45,151                                                                                       
 shares of Common Stock issuable under our 2016 Plan and our 2024 Plan, which includes 45,141 
 shares of Common Stock reserved for issuance under our 2016 Plan and our 2024 Plan;          |

| ● | 5,272                                                                                        
 shares of Common Stock issuable under our 2024 ESPP, which includes 527,182 shares of Common 
 Stock reserved for issuance under our 2024 ESPP;                                             |

| ● | 95,175                                                                                     
 shares of Common Stock issuable upon the exercise of Public Warrants and Private Placement 
 Warrants;                                                                                  |

| ● | 87,879                                                                                       
 shares of Common Stock issuable upon the exercise of Common Warrants issued in the offerings 
 of our Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock; and  |

| ● | 1,345,679                                                                                 
 shares of Common Stock issuable upon conversion of the Series A Preferred Stock, Series B 
 Preferred Stock, and Series C Preferred Stock, including 497,977 shares issuable upon the 
 exercise of Preferred Warrants.                                                           |

To the extent any outstanding
options are exercised, new options or other equity awards are issued under our equity incentive plans, or we issue additional equity
or convertible securities in the future, there will be further dilution to new investors participating in this offering.

<div align='center'>73

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</div>

PBAX, and after the Business
Combination, CERo, is providing the following unaudited pro forma condensed combined financial information to aid you in your analysis
of the financial aspects of the Business Combination and related transactions. The following unaudited pro forma condensed financial
information presents the combination of the financial information of PBAX and Legacy CERo adjusted to give effect to the Business Combination
and related transactions. The following unaudited pro forma condensed combined financial information has been prepared